The α-chemokine CXCL14 is up-regulated in the sciatic nerve of a mouse model of Charcot-Marie-Tooth disease type 1A and alters myelin gene expression in cultured Schwann cells

Neurobiology of Disease

Volumn 33, Issue 3, 2009, Pages 448-458

  Barbaria, Elena M ^a   Kohl, Bianca ^b   Buhren, Bettina A ^a   Hasenpusch Theil, Kerstin ^a   Kruse, Fabian ^a   Küry, Patrick ^a   Martini, Rudolf ^b   Müller, Hans Werner ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

C61 mouse mutant; CMT1A; CXCL14; Cyclin D1; Myelin; Myelination; Ninjurin 1; Pmp22; Schwann cells; Tenascin

Indexed keywords

CXCL14 CHEMOKINE; PERIPHERAL MYELIN PROTEIN 22;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; HEREDITARY MOTOR SENSORY NEUROPATHY; HEREDITARY MOTOR SENSORY NEUROPATHY TYPE 1A; IMMUNODETECTION; IMMUNOLOCALIZATION; MICROARRAY ANALYSIS; MORPHOMETRICS; MOUSE; MYELINATION; NONHUMAN; PERIPHERAL NERVE; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; RAT; SCHWANN CELL; SCIATIC NERVE; TRANSGENIC ANIMAL; UPREGULATION; WILD TYPE;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CHARCOT-MARIE-TOOTH DISEASE; CHEMOKINES, CXC; DISEASE MODELS, ANIMAL; GENE EXPRESSION; MICE; MICE, TRANSGENIC; MYELIN BASIC PROTEINS; MYELIN P0 PROTEIN; MYELIN PROTEINS; NERVE FIBERS, MYELINATED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECOMBINANT PROTEINS; RNA INTERFERENCE; RNA, MESSENGER; SCHWANN CELLS; SCIATIC NERVE; UP-REGULATION;

EID: 60849116121     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2008.11.014     Document Type: Article

References (49)

1. Adlkofer K., Martini R., Aguzzi A., Zielasek J., Toyka K.V., and Suter U. Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice. Nat. Genet. 11 (1995) 274-280
2. Atanasoski S., Shumas S., Dickson C., Scherer S.S., and Suter U. Differential cyclin D1 requirements of proliferating Schwann cells during development and after injury. Mol. Cell. Neurosci. 18 (2001) 581-592
3. Atanasoski S., Scherer S.S., Nave K.A., and Suter U. Proliferation of Schwann cells and regulation of cyclin D1 expression in an animal model of Charcot-Marie-Tooth disease type 1A. J. Neurosci. Res. 67 (2002) 443-449
4. Berger P., Young P., and Suter U. Molecular cell biology of Charcot-Marie-Tooth disease. Neurogenetics 4 (2002) 1-15
5. Boerkoel C.F., Takashima H., Garcia C.A., Olney R.K., Johnson J., Berry K., Russo P., Kennedy S., Teebi A.S., Scavina M., Williams L.L., Mancias P., Butler I.J., Krajewski K., Shy M., and Lupski J.R. Charcot-Marie-Tooth disease and related neuropathies: mutation distribution and genotype-phenotype correlation. Ann. Neurol. 51 (2002) 190-201
6. Brockes J.P., Fields K.L., and Raff M.C. Studies on cultured rat Schwann cells. I. Establishment of purified populations from cultures of peripheral nerve. Brain Res. 165 (1979) 105-118
7. Burry R.W. Specificity controls for immunocytochemical methods. J. Histochem. Cytochem. 48 (2000) 163-166
8. Fruttiger M., Montag D., Schachner M., and Martini R. Crucial role for the myelin-associated glycoprotein in the maintenance of axon-myelin integrity. Eur. J. Neurosci. 7 (1995) 511-515
9. Fruttiger M., Schachner M., and Martini R. Tenascin-C expression during Wallerian degeneration in C57BL/Wlds mice: possible implications for axonal regeneration. J. Neurocytol. 24 (1995) 1-14
10. Fischer S., Kleinschnitz C., Müller M., Kobsar I., Ip C.W., Rollins B., and Martini R. Monocyte chemoattractant protein-1 is a pathogenic component in a model for a hereditary peripheral neuropathy. Mol. Cell. Neurobiol. 37 (2008) 359-366
11. Gabreels-Festen A.A., Bolhuis P.A., Hoogendijk J.E., Valentijn L.J., Eshuis E.J., and Gabreels F.J. Charcot-Marie-Tooth disease type 1A: morphological phenotype of the 17p duplication versus PMP22 point mutations. Acta Neuropathol. 90 (1995) 645-649
12. Garbay B., Heape A.M., Sargueil F., and Cassagne C. Myelin synthesis in the peripheral nervous system. Prog. Neurobiol. 61 (2000) 267-304
13. Ghislain J., and Charnay P. Control of myelination in Schwann cells: a Krox20 cis-regulatory element integrates Oct6, Brn2 and Sox10 activities. EMBO Rep. 7 (2006) 52-58
14. Giambonini-Brugnoli G., Buchstaller J., Sommer L., Suter U., and Mantei N. Distinct disease mechanisms in peripheral neuropathies due to altered peripheral myelin protein 22 gene dosage or a Pmp22 point mutation. Neurobiol. Dis. 18 (2005) 656-668
15. Hanemann C.O., Gabreels-Festen A.A., Stoll G., and Muller H.W. Schwann cell differentiation in Charcot-Marie-Tooth disease type 1A (CMT1A): normal number of myelinating Schwann cells in young CMT1A patients and neural cell adhesion molecule expression in onion bulbs. Acta Neuropathol. 94 (1997) 310-315
16. Heinen A., Kremer D., Göttle P., Kruse F., Hasse B., Lehmann H., Hartung H.P., and Küry P. The cyclin-dependent kinase inhibitor p57kip2 is a negative regulator of Schwann cell differentiation and in vitro myelination. Proc. Natl. Acad. Sci. U. S. A. (2008)
17. Hromas R., Broxmeyer H.E., Kim C., Nakshatri H., Christopherson II K., Azam M., and Hou Y.H. Cloning of BRAK, a novel divergent CXC chemokine preferentially expressed in normal versus malignant cells. Biochem. Biophys. Res. Commun. 255 (1999) 703-706
18. Huxley C., Passage E., Manson A., Putzu G., Figarella-Branger D., Pellissier J.F., and Fontes M. Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA. Hum. Mol. Genet. 5 (1996) 563-569
19. Huxley C., Passage E., Robertson A.M., Youl B., Huston S., Manson A., Saberan-Djoniedi D., Figarella-Branger D., Pellissier J.F., Thomas P.K., and Fontes M. Correlation between varying levels of PMP22 expression and the degree of demyelination and reduction in nerve conduction velocity in transgenic mice. Hum. Mol. Genet. 7 (1998) 449-458
20. Ip C.W., Kroner A., Bendszus M., Leder C., Kobsar I., Fischer S., Wiendl H., Nave K.A., and Martini R. Immune cells contribute to myelin degeneration and axonopathic changes in mice overexpressing proteolipid protein in oligodendrocytes. J. Neurosci. 26 (2006) 8206-8216
21. Irizarry R.A., Hobbs B., Collin F., Beazer-Barclay Y.D., Antonellis K.J., Scherf U., and Speed T.P. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4 (2003) 249-264
22. Jessen K.R., and Mirsky R. The origin and development of glial cells in peripheral nerves. Nat. Rev. Neurosci. 6 (2005) 671-682
23. Kobsar I., Hasenpusch-Theil K., Wessig C., Müller H.W., and Martini R. Evidence for macrophage-mediated myelin disruption in an animal model for Charcot-Marie-Tooth neuropathy type 1A. J. Neurosci. Res. 81 (2005) 857-864
24. Kubo T., Yamashita T., Yamaguchi A., Hosokawa K., and Tohyama M. Analysis of genes induced in peripheral nerve after axotomy using cDNA microarrays. J. Neurochem. 82 (2002) 1129-1136
25. Kurth I., Willimann K., Schaerli P., Hunziker T., Clark-Lewis I., and Moser B. Monocyte selectivity and tissue localization suggests a role for breast and kidney-expressed chemokine (BRAK) in macrophage development. J. Exp. Med. 194 (2001) 855-861
26. Li C., and Wong W.H. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 31-36
27. Liang G., Cline G.W., and Macica C.M. IGF-1 stimulates de novo fatty acid biosynthesis by Schwann cells during myelination. Glia 55 (2007) 632-641
28. Lupski J.R., de Oca-Luna R.M., Slaugenhaupt S., Pentao L., Guzzetta V., Trask B.J., Saucedo-Cardenas O., Barker D.F., Killian J.M., Garcia C.A., Chakravarti A., and Patel P.I. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 66 (1991) 219-232
29. Magyar J.P., Martini R., Ruelicke T., Aguzzi A., Adlkofer K., Dembic Z., Zielasek J., Toyka K.V., and Suter U. Impaired differentiation of Schwann cells in transgenic mice with increased PMP22 gene dosage. J. Neurosci. 16 (1996) 5351-5360
30. Martini R., Schachner M., and Faissner A. Enhanced expression of the extracellular matrix molecule J1/tenascin in the regenerating adult mouse sciatic nerve. J. Neurocytol. 19 (1990) 601-616
31. Morgan L., Jessen K.R., and Mirsky R. The effects of cAMP on differentiation of cultured Schwann cells: progression from an early phenotype (04+) to a myelin phenotype (P0+, GFAP-, N-CAM-, NGF-receptor-) depends on growth inhibition. J. Cell Biol. 112 (1991) 457-467
32. Nagarajan R., Le N., Mahoney H., Araki T., and Milbrandt J. Deciphering peripheral nerve myelination by using Schwann cell expression profiling. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 8998-9003
33. Nelis E., Van Broeckhoven C., De Jonghe P., Lofgren A., Vandenberghe A., Latour P., Le Guern E., Brice A., Mostacciuolo M.L., Schiavon F., Palau F., Bort S., Upadhyaya M., Rocchi M., Archidiacono N., Mandich P., Bellone E., Silander K., Savontaus M.L., Navon R., Goldberg-Stern H., Estivill X., Volpini V., Friedl W., Gal A., et al. Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study. Eur. J. Hum. Genet. 4 (1996) 25-33
34. Niemann S., Sereda M.W., Suter U., Griffiths I.R., and Nave K.A. Uncoupling of myelin assembly and Schwann cell differentiation by transgenic overexpression of peripheral myelin protein 22. J. Neurosci. 20 (2000) 4120-4128
35. Perea J., Robertson A., Tolmachova T., Muddle J., King R.H., Ponsford S., Thomas P.K., and Huxley C. Induced myelination and demyelination in a conditional mouse model of Charcot-Marie-Tooth disease type 1A. Hum. Mol. Genet. 10 (2001) 1007-1018
36. Porter S., Clark M.B., Glaser L., and Bunge R.P. Schwann cells stimulated to proliferate in the absence of neurons retain full functional capability. J. Neurosci. 6 (1986) 3070-3078
37. Raeymaekers P., Timmerman V., Nelis E., De Jonghe P., Hoogendijk J.E., Baas F., Barker D.F., Martin J.J., De Visser M., Bolhuis P.A., et al. Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). The HMSN Collaborative Research Group. Neuromuscul. Disord. 1 (1991) 93-97
38. Robertson A.M., Huxley C., King R.H., and Thomas P.K. Development of early postnatal peripheral nerve abnormalities in Trembler-J and PMP22 transgenic mice. J. Anat. 195 Pt. 3 (1999) 331-339
39. Robertson A.M., Perea J., McGuigan A., King R.H., Muddle J.R., Gabreels-Festen A.A., Thomas P.K., and Huxley C. Comparison of a new pmp22 transgenic mouse line with other mouse models and human patients with CMT1A. J. Anat. 200 (2002) 377-390
40. Sereda M., Griffiths I., Puhlhofer A., Stewart H., Rossner M.J., Zimmerman F., Magyar J.P., Schneider A., Hund E., Meinck H.M., Suter U., and Nave K.A. A transgenic rat model of Charcot-Marie-Tooth disease. Neuron 16 (1996) 1049-1060
41. Shy M.E. Charcot-Marie-Tooth disease: an update. Curr. Opin. Neurol. 17 (2004) 579-585
42. Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin. Genet. 6 (1974) 98-118
43. Sleeman M.A., Fraser J.K., Murison J.G., Kelly S.L., Prestidge R.L., Palmer D.J., Watson J.D., and Kumble K.D. B cell- and monocyte-activating chemokine (BMAC), a novel non-ELR alpha-chemokine. Int. Immunol. 12 (2000) 677-689
44. Spreyer P., Kuhn G., Hanemann C.O., Gillen C., Schaal H., Kuhn R., Lemke G., and Müller H.W. Axon-regulated expression of a Schwann cell transcript that is homologous to a 'growth arrest-specific' gene. EMBO J. 10 (1991) 3661-3668
45. Timmerman V., Nelis E., Van Hul W., Nieuwenhuijsen B.W., Chen K.L., Wang S., Ben Othman K., Cullen B., Leach R.J., Hanemann C.O., et al. The peripheral myelin protein gene PMP-22 is contained within the Charcot-Marie-Tooth disease type 1A duplication. Nat. Genet. 1 (1992) 171-175
46. Verheijen M.H., Chrast R., Burrola P., and Lemke G. Local regulation of fat metabolism in peripheral nerves. Genes Dev. 17 (2003) 2450-2464
47. Vigo T., Nobbio L., Hummelen P.V., Abbruzzese M., Mancardi G., Verpoorten N., Verhoeven K., Sereda M.W., Nave K.A., Timmerman V., and Schenone A. Experimental Charcot-Marie-Tooth type 1A: a cDNA microarrays analysis. Mol. Cell Neurosci. 28 (2005) 703-714
48. Wagner-Recio M., Toews A.D., and Morell P. Tellurium blocks cholesterol synthesis by inhibiting squalene metabolism: preferential vulnerability to this metabolic block leads to peripheral nervous system demyelination. J. Neurochem. 57 (1991) 1891-1901
49. Wu Z. A model-based background adjustment for oligonucleotide expression arrays. J. Am. Stat. Assoc. 99 909 (2004) 909-917